An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. [electronic resource]
Producer: 20080212Description: 4044-54 p. digitalISSN:- 0021-9738
- Animals
- Benzamides
- Cardiotoxins -- chemistry
- Drug Screening Assays, Antitumor
- Fusion Proteins, bcr-abl
- Gastrointestinal Stromal Tumors -- drug therapy
- Heart Diseases -- chemically induced
- Humans
- Imatinib Mesylate
- K562 Cells
- MAP Kinase Kinase 4 -- antagonists & inhibitors
- Neoplasms, Experimental -- drug therapy
- Piperazines -- adverse effects
- Protein Kinase Inhibitors -- adverse effects
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins c-kit -- metabolism
- Pyrimidines -- adverse effects
- Rats
- Rats, Sprague-Dawley
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.